Wondering how to knock that investor pitch out of the park? In this next installment of the “All About Grants” podcast series, small business innovators will get a front row seat to hear how to prepare for private investment (MP3 / Transcript). Dr. Ethel Ruben, NIH’s Entrepreneur-In-Residence, steps up to the plate and shares insights on who these investors are, how they decide on what innovations to invest in the biomedical commercial space, and some valuable tips and tricks to improve the accuracy of your investor pitch. Continue reading
This dynamic, national, three-day event is designed to educate attendees about America’s Largest Seed Fund and how to access federal resources, develop competitive proposals, and secure awards. At $1 billion dollars of annual HHS funding, this is one of the largest sources of early-stage capital for life science technology commercialization in the United States. Hosted by the Dallas Regional Chamber, A Better Tomorrow: Big Ideas in BioTech will be relevant to a diverse audience, including biomedical entrepreneurs; principal investigators; grants and contracts administrators; and industry partners and investors. Continue reading
At NIH, we maintain a broad and diverse portfolio of biomedical and behavioral research. To turn discovery into health, promising technologies must move from the laboratory into clinical trials, into the marketplace, into the doctor’s office, and into our every-day lives. A key way to transition promising technologies out of the laboratory is through the commercialization process. Continue reading
We were pleased to see the interest in our recent blog on the unique number of investigators applying for and receiving NIH research project grants (RPGs). Some of you (through the blog page or through other media) have asked about whether we have similar data for our Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) program. We have generated analogous figures for SBIR and STTR grants, and today’s post shares this investigation of the question, “How many unique researchers are seeking SBIR/STTR funding?” …. Continue reading
In the rapidly evolving world of modern medicine, it is important that the transition of basic scientific discoveries into new medical treatments takes place with both precision and speed.
NIH’s Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) programs – which I’ve discussed a few times on the blog before – are a key part of NIH’s translational research portfolio. …. Continue reading
Tom Kalil is Deputy Director for Technology and Innovation in the White House Office of Science and Technology Policy (OSTP). — We are delighted to announce a new collaboration between the National Institutes of Health (NIH) and the National Science Foundation (NSF) to empower entrepreneurial scientists and advance the Lab-to-Market priorities set forth in the President’s Management Agenda. The Federal government invests over $130 billion on research and development (R&D) each year, and the President’s 2015 budget supports a sustained commitment to accelerate the transfer of promising Federally-funded technologies from the laboratory to the commercial marketplace. Continue reading
Since the last time I’ve written about our small business research programs, there have been a lot of important changes as a result of the Congressional reauthorization that mandated Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding requirements through fiscal year 2017. …. We have been working diligently alongside the Small Business Administration to put these changes into effect for NIH, as described on the SBIR/STTR Reauthorization Act of 2011: NIH Implementation of Key Changes website. As the 2014 HHS-wide SBIR and STTR Omnibus solicitations were announced last week, I thought it would be good to highlight some of these important reforms. …. Continue reading